Eli M. Wallace - 01 Jan 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Role: Chief Executive Officer, Director
Signature: /s/ Aaron Chan, Attorney-in-Fact
Issuer symbol: HLXB
Transactions as of: 01 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2026, 19:22:35 UTC
Previous filing: 12 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wallace Eli M.	Chief Executive Officer, Director	BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO	/s/ Aaron Chan, Attorney-in-Fact	05 Jan 2026	0001776352

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BBOT	Stock Option (Right to Buy)	Award	$0	+1,114,400		$0.000000	1,114,400	01 Jan 2026	Common Stock	1,114,400	$12.52	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	69,650 of the shares underlying the option vested on January 2, 2026. Thereafter, 1/48th of the shares underlying the option will vest monthly, with full vesting scheduled for October 2, 2029, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.